Smartlab Europe

Cristal Therapeutics Announces Appointment of Jeroen Tonnaer as Chief Business Officer

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Novartis China Investment Expands R&D and Manufacturing

Novartis is stepping up its presence in China with...

UK Backs Respiratory Transformation Partnership with £10m

The NHS has partnered with leading pharmaceutical companies to...

The Invisible Costs Undermining Pharma Profit Margins and the Digital Fixes Gaining Traction

Pharmaceutical companies spend extraordinary amounts optimising what they can...
- Advertisement -

Cristal Therapeutics, a privately-held life sciences company developing novel nanotherapeutics against cancer and other diseases, by using its patented CriPec® platform announced today the appointment of Jeroen Tonnaer as new Chief Business Officer responsible for Cristal Therapeutics’ business development, partnering and licensing activities.

Jeroen obtained an MSc in biology, a PhD in pharmacology and is a Certified Licensing Professional (CLP™). As an employee of major pharma companies, he built a broad knowledge and expertise in drug discovery & development and research strategy. He has extensive international and cross-cultural partnering & licensing expertise.

As a neuroscientist Jeroen joined Organon in 1982. He held further positions as Head DMPK, Executive Director Toxicology, and Executive Director Global Research Alliances. Subsequently he was Head Discovery Collaborations Europe for Schering-Plough. Following Schering-Plough’s acquisition by Merck & Co. (called MSD outside the US and Canada), Jeroen joined Merck’s Worldwide Licensing organization in February 2010 to become head of the European External Scientific Affairs team. Since then this team has been the driver in the identification and execution of several multimillion-$$ licensing and partnering deals

Latest stories

Related stories

Novartis China Investment Expands R&D and Manufacturing

Novartis is stepping up its presence in China with...

UK Backs Respiratory Transformation Partnership with £10m

The NHS has partnered with leading pharmaceutical companies to...

The Invisible Costs Undermining Pharma Profit Margins and the Digital Fixes Gaining Traction

Pharmaceutical companies spend extraordinary amounts optimising what they can...

SGD Pharma Advances Nasal Drug Delivery with Prince Deal

SGD Pharma has entered into a Franco-American OEM collaboration...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »